+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Pharmacokinetics of the beta-carboline norharman in man

Pharmacokinetics of the beta-carboline norharman in man

Life Sciences 69(18): 2113-2121

In healthy subjects, pharmacokinetics were characterised using single oral and sublingual administrations of the beta-carboline norharman. For this purpose, norharman levels in blood plasma were measured up to 90-105 min after both routes of administration. Dose proportionality of three different single oral doses of norharman (7, 65 and 110 microg/kg) administered as 0.52 and 5 mg capsules was evaluated at 8 time points. Peak levels were attained at 30 min after the oral load of norharman. Mean relative availabilities determined by the area under the curve (AUC) procedure were 14.3 and 98.0 nmol.min/l after oral dosing of 7 and 65 microg/kg, respectively. AUC values in women were 3-4 times higher than in men. Sublingual dosing of 6.5 and 13 microg/kg norharman encapsulated in 5 mg of cyclodextrins resulted in a much higher mean AUC and a more rapid absorption. Mean AUC after sublingual administration of 6.5 microg/kg was 929.8 nmol.min/kg and plasma levels were maximal 10-15 min after norharman was given. Moreover, apparently no sex difference was found using this way of application. Norharman disappeared from the plasma with half-lifes of 25-35 min, irrespective of the route of administration. Even at the highest measured norharman levels of 53 nmol/l plasma, no behavioral effects were observed. In addition, the subjects did neither report any effects nor any side-effects during the experiment. This is the first study in which the kinetics of ingested norharman have been measured in humans.

(PDF emailed within 1 workday: $29.90)

Accession: 011137980

Download citation: RISBibTeXText

PMID: 11669455

Related references

Pharmacokinetics of the b-carboline norharman in man. Life Sciences 69(18): 13-21, 2001

Norharman, an indoleamine-derived beta-carboline, but not Trp-P-2, a gamma-carboline, induces apoptotic cell death in human neuroblastoma SH-SY5Y cells. Journal of Neural Transmission 108(8-9): 943-953, 2001

Occurrence and partition of the beta-carboline norharman in rat organs. Life Sciences 52(25): 2045-2054, 1993

Tetrahydro-beta-carboline-3-carboxylic acid compounds in fish and meat: possible precursors of co-mutagenic beta-carbolines norharman and harman in cooked foods. Food Additives and Contaminants 17(10): 859-866, 2000

Isolation and identification of two (3H)norharman-((3H)beta-carboline)-binding proteins from rat liver. Journal of Chromatography B 784(1): 155-168, 2003

Isolation and identification of two [(3)H]norharman- ([(3)H]beta-carboline)-binding proteins from rat liver. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 784(1): 155-168, 2002

Kindling of seizures with norharman, a beta-carboline ligand of benzodiazepine receptors. European Journal of Pharmacology 88(1): 131-134, 1983

Plasma norharman (beta-carboline) levels are elevated in chronic alcoholics. Alcoholism, Clinical and Experimental Research 15(3): 553-559, 1991

Quantitative autoradiography of [3H]norharman [( 3H]beta-carboline) binding sites in the rat brain. Journal of Chemical Neuroanatomy 3(1): 19-24, 1990

High affinity binding sites for tritiated norharman beta carboline in rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology 335(SUPPL): R96, 1987

3H]norharman ([3H]beta-carboline) binds reversibly and with high affinity to a specific binding site in rat liver. Neurochemical Research 18(9): 1029-1031, 1993

Demonstration of a distinct class of high-affinity binding sites for [3H]norharman [( 3H]beta-carboline) in the rat brain. European Journal of Pharmacology 147(2): 163-171, 1988

The high-affinity binding of (3H)norharman ((3H)beta-carboline) to the ethanol-inducible cytochrome P450 2E1 in rat liver. Biochemical Pharmacology 57(5): 511-520, 1999

Norharman (beta-carboline) as a potent inhibitory ligand for steroidogenic cytochromes P450 (CYP11 and CYP17). European Journal of Pharmacology 250(1): R1-R3, 1993

The high-affinity binding of [3H]norharman ([3H]beta-carboline) to the ethanol-inducible cytochrome P450 2E1 in rat liver. Biochemical Pharmacology 57(5): 511-520, 1999